Cellectis (NASDAQ:CLLS) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Cellectis (NASDAQ:CLLS - Free Report) from a hold rating to a sell rating in a research report report published on Thursday morning.

Separately, Barclays lowered their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th.

Cellectis Trading Up 0.3%

Shares of CLLS traded up $0.01 during trading hours on Thursday, reaching $1.48. 41,031 shares of the company traded hands, compared to its average volume of 142,616. The stock's fifty day moving average price is $1.42 and its 200 day moving average price is $1.57. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market cap of $81.99 million, a price-to-earnings ratio of -1.13 and a beta of 3.11. Cellectis has a 12-month low of $1.10 and a 12-month high of $2.81.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The company had revenue of $12.03 million for the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. Sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

A number of hedge funds have recently added to or reduced their stakes in CLLS. Wells Fargo & Company MN raised its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. OLD Mission Capital LLC bought a new position in shares of Cellectis during the first quarter valued at approximately $31,000. Acadian Asset Management LLC increased its holdings in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock valued at $55,000 after buying an additional 26,461 shares during the period. Millennium Management LLC bought a new position in Cellectis in the fourth quarter worth approximately $962,000. Finally, B Group Inc. purchased a new stake in Cellectis during the fourth quarter worth $5,547,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.